Dexcom (NSDQ:DXCM) shares fell today after the company issued conservative guidance for its expected revenue in 2018. The company also posted Street-beating preliminary results for its fourth quarter and full-year 2017 revenues.
The company is facing competition in the new year after the FDA approval of Abbott‘s (NYSE:ABT) continuous glucose monitor, the FreeStyle Libre. But chief executive Kevin Sayer points to the company’s many partnerships and growing sales numbers as evidence that the CGM-maker is doing just fine.
Get the full story at our sister site, Drug Delivery Business News.
The post Dexcom posts cautious 2018 forecast despite Street-beating Q4, FY17 prelims appeared first on MassDevice.
from MassDevice http://ift.tt/2AKtVm4
Cap comentari:
Publica un comentari a l'entrada